Internal Medicine Update

Internal Medicine Update updates in internal medicine

15/07/2025

The Patient Did Well — So the Insurance Company Won’t Pay
Dr. Paul Sax highlights the frustrations of peer-to-peer discussions with insurance companies. https://jwat.ch/4eRzVyc

21/11/2024

Metformin was associated with a lower rate of asthma attacks, with further reductions with the use of GLP-1RA. https://ja.ma/40OTLVZ

21/11/2024

Among hospitalized patients with cirrhosis and ascites, early diagnostic paracentesis within 12 to 24 hours was associated with lower in-hospital mortality, shorter hospital length of stay, and fewer acute kidney injuries. https://jwat.ch/4eD6n5B

10/11/2024

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are incorporating the medicines into preconception care plans.

10/11/2024

In a meta-analysis that included over 3,700 patients with heart failure with preserved ejection fraction (HFpEF) and obesity, semaglutide lowered the rate of worsening HF events compared with placebo.

In a subgroup analysis, patients with body mass index ≥35 kg/m2 were more likely to benefit from semaglutide than those with lower body mass index. In patients with HFpEF and obesity, we suggest a GLP-1 receptor agonist and lifestyle interventions for weight loss rather than lifestyle interventions alone.

Stay with What's New in : https://ow.ly/n4Me50TYtOS

07/11/2024

In a placebo-controlled trial, frequency of nocturnal leg cramps was significantly lower with vitamin K2. https://jwat.ch/48zxNbq

07/11/2024

🚨 New Clinical Practice Update! 🚨

Our latest guidance provides new insights into when to use potassium-competitive acid blockers (P-CABs). Spoiler alert: P-CABs should not typically represent the first choice for treating all patients with heartburn or acid-related disorders at present.

Key takeaways:

🔹P-CABs should generally be used for the eradication of H. pylori infection and considered for the treatment of severe erosive esophagitis and for patients with GERD who fail twice-daily PPI therapy.

🔹P-CABs may be considered for other acid-related conditions if other treatments haven’t worked, but factors like dosage, availability, cost, and safety must be carefully evaluated.

Check out the full guidance: https://ow.ly/Qg7650U1t1A.

Watch authors Drs. Amit Patel and Loren Laine discuss the highlights: https://ow.ly/Cr2m50U1t1z.

07/11/2024

Results of this post hoc analysis suggest that treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation/behavior vs placebo. https://ja.ma/3V3bjtR

06/11/2024

A new analysis from Novo Nordisk’s SELECT trial points to the potential for cost savings.

Address

Nasr City
Cairo
11254

Website

Alerts

Be the first to know and let us send you an email when Internal Medicine Update posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Internal Medicine Update:

Shortcuts

Share

Category